Brief: Kaleido Biosciences Reports Positive Results From Non-IND Study Of KB109 In Patients With Mild-To-Moderate Covid-19

Kaleido Biosciences

24/03/2021 11:00

March 24 (Reuters) - Kaleido Biosciences:
    * KALEIDO BIOSCIENCES - REPORTED POSITIVE RESULTS FROM
NON-IND
STUDY OF KB109 IN PATIENTS WITH MILD-TO -MODERATE COVID-19
    * KALEIDO BIOSCIENCES - KB109 REDUCED HEALTHCARE UTILIZATION
BY
ABOUT 62% AMONG PATIENTS WITH ONE OR MORE COMORBIDITIES AND
ABOUT 51% OVERALL
    * KALEIDO BIOSCIENCES - KB109 SHOWED REDUCTION IN RECOVERY
TIME IN
PATIENTS WITH MILD-TO-MODERATE COVID-19 AND ONE OR MORE
COMORBIDITIES
    * KALEIDO BIOSCIENCES - INTENDS TO FILE INVESTIGATIONAL NEW
DRUG
APPLICATION, WITH GOAL OF ADVANCING KB109 INTO A PIVOTAL
REGISTRATION PROGRAM
    * KALEIDO BIOSCIENCES - CONTINUING TO STUDY KB109 IMPACT ON
THE
INCIDENCE OF ‘LONG-COVID’, WHERE SYMPTOMS PERSIST IN PATIENTS
FOR WEEKS AND MONTHS
    * KALEIDO BIOSCIENCES - KB109 SHOWED OVERALL FAVORABLE
SAFETY AND
TOLERABILITY PROFILE WITH NO UNEXPECTED TREATMENT-RELATED
ADVERSE EVENTS
    * KALEIDO BIOSCIENCES - KB109 TARGETS HOST IMMUNE SYSTEM AND
IS
LIKELY TO DEMONSTRATE SIMILAR RESULTS AGAINST EMERGING VIRUS
VARIANTS

Source text for Eikon:  urn:newsml:reuters.com:*:nGNX1PjNTb
Further company coverage:  KLDO.O 

 ((Reuters.Briefs@thomsonreuters.com;))